The pharmacokinetics of anthocyanins and their metabolites in humans. 2014

R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
Department of Nutrition, Norwich Medical School, University of East Anglia, Norwich, UK.

OBJECTIVE Anthocyanins are phytochemicals with reported vasoactive bioactivity. However, given their instability at neutral pH, they are presumed to undergo significant degradation and subsequent biotransformation. The aim of the present study was to establish the pharmacokinetics of the metabolites of cyanidin-3-glucoside (C3G), a widely consumed dietary phytochemical with potential cardioprotective properties. METHODS A 500 mg oral bolus dose of 6,8,10,3',5'-(13)C5-C3G was fed to eight healthy male participants, followed by a 48 h collection (0, 0.5, 1, 2, 4, 6, 24, 48 h) of blood, urine and faecal samples. Samples were analysed by HPLC-ESI-MS/MS with elimination kinetics established using non-compartmental pharmacokinetic modelling. RESULTS Seventeen (13)C-labelled compounds were identified in the serum, including (13)C5-C3G, its degradation products, protocatechuic acid (PCA) and phloroglucinaldehyde (PGA), 13 metabolites of PCA and 1 metabolite derived from PGA. The maximal concentrations of the phenolic metabolites (Cmax ) ranged from 10 to 2000 nM, between 2 and 30 h (tmax) post-consumption, with half-lives of elimination observed between 0.5 and 96 h. The major phenolic metabolites identified were hippuric acid and ferulic acid, which peaked in the serum at approximately 16 and 8 h respectively. CONCLUSIONS Anthocyanins are metabolized to a structurally diverse range of metabolites that exhibit dynamic kinetic profiles. Understanding the elimination kinetics of these metabolites is key to the design of future studies examining their utility in dietary interventions or as therapeutics for disease risk reduction.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005960 Glucosides A GLYCOSIDE that is derived from GLUCOSE. Glucoside
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
November 2019, Molecules (Basel, Switzerland),
R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
July 1986, Cancer treatment reports,
R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
January 2009, Annals of nutrition & metabolism,
R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
January 1988, Biopharmaceutics & drug disposition,
R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
September 1991, Therapeutic drug monitoring,
R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
January 1994, Acta pharmaceutica Hungarica,
R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
August 2019, Antioxidants (Basel, Switzerland),
R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
January 2006, Drug metabolism and drug interactions,
R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
January 1978, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
R M de Ferrars, and C Czank, and Q Zhang, and N P Botting, and P A Kroon, and A Cassidy, and C D Kay
January 1992, Pharmacology,
Copied contents to your clipboard!